AI assistant
Pacira BioSciences, Inc. — Director's Dealing 2021
Dec 18, 2021
32125_dirs_2021-12-17_431b799c-a8e9-4643-a11d-135836ee1013.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Pacira BioSciences, Inc. (PCRX)
CIK: 0001396814
Period of Report: 2021-12-07
Reporting Person: MOLLOY ANTHONY (Chief Lgl & Compliance Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 15550 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $60.96 | 2031-06-09 | Common Stock (15000) | Direct | |
| Stock Option (Right to Buy) | $68.89 | 2031-04-05 | Common Stock (10000) | Direct | |
| Stock Option (Right to Buy) | $47.65 | 2030-06-09 | Common Stock (22000) | Direct | |
| Stock Option (Right to Buy) | $43.54 | 2029-06-05 | Common Stock (26300) | Direct | |
| Stock Option (Right to Buy) | $38.35 | 2028-06-13 | Common Stock (8750) | Direct | |
| Stock Option (Right to Buy) | $34.375 | 2028-05-02 | Common Stock (3125) | Direct | |
| Stock Option (Right to Buy) | $44.20 | 2027-06-14 | Common Stock (10000) | Direct | |
| Stock Option (Right to Buy) | $40.34 | 2026-06-15 | Common Stock (3000) | Direct | |
| Stock Option (Right to Buy) | $67.00 | 2025-09-15 | Common Stock (4000) | Direct | |
| Stock Option (Right to Buy) | $79.43 | 2025-06-03 | Common Stock (5500) | Direct | |
| Stock Option (Right to Buy) | $81.00 | 2024-06-03 | Common Stock (5000) | Direct | |
| Stock Option (Right to Buy) | $56.32 | 2024-01-03 | Common Stock (12500) | Direct |
Footnotes
F1: Represents 15,550 unvested restricted stock units. The unvested restricted stock units vest as follows: (i) 6,000 restricted stock units that vest in four equal annual installments on June 3, 2022, June 3, 2023, June 3, 2024 and June 3, 2025, (ii) 6,600 restricted stock units that vest in three equal annual installments on June 3, 2022, June 3, 2023 and June 3, 2024, (iii) 2,200 restricted stock units that vest in two equal annual installments on June 3, 2022 and June 3, 2023 and (iv) 750 restricted stock units that vest on June 3, 2022, in each case, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F2: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.
F3: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date.
F4: The option vested and became exercisable as to 25% of the option shares on December 9, 2014 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months.